Clinical management of drug-drug interactions in HCV therapy: Challenges and solutions

Journal of Hepatology

Volumn 58, Issue 4, 2013, Pages 792-800

  Burger, David ^a   Back, David ^b   Buggisch, Peter ^c   Buti, Maria ^d   Craxí, Antonio ^e   Foster, Graham ^f   Klinker, Hartwig ^g   Larrey, Dominique ^h   Nikitin, Igor ⁱ   Pol, Stanislas ^j   Puoti, Massimo ^k   Romero Gómez, Manuel ^l   Wedemeyer, Heiner ^m   Zeuzem, Stefan ⁿ  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c DEPARTMENT OF CARDIOLOGY   (Germany)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e UNIVERSITY OF PALERMO   (Italy)

^f QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^g UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^h UNIV MONTPELLIER   (France)

ⁱ PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^j Université Paris Descartes ^*  (France)

^k OSPEDALE NIGUARDA CA GRANDA   (Italy)

^l HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^m LEIBNIZ UNIVERSITY HANNOVER   (Germany)

ⁿ UNIVERSITY HOSPITAL FRANKFURT   (Germany)

more..

Author keywords

Boceprevir; Drug interactions; Hepatitis C virus infection; Pharmacokinetics; Telaprevir

Indexed keywords

BOCEPREVIR; INTERFERON; MIDAZOLAM; NICARDIPINE; NIFEDIPINE; NISOLDIPINE; PHENOBARBITAL; PHENYTOIN; PIMOZIDE; POSACONAZOLE; PREDNISONE; PROPAFENONE; PROTEINASE INHIBITOR; QUINIDINE; RAPAMYCIN; RIBAVIRIN; RIFABUTIN; RIFAMPICIN; SALMETEROL; SILDENAFIL; SIMVASTATIN; SORAFENIB; SOTALOL; SUNITINIB; TACROLIMUS; TADALAFIL; TELAPREVIR; TELBIVUDINE; TELITHROMYCIN; UNINDEXED DRUG;

ANTIVIRAL THERAPY; AREA UNDER THE CURVE; BLOOD SAMPLING; CLINICAL TRIAL (TOPIC); DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL; MAXIMUM PLASMA CONCENTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW;

ANTI-INFECTIVE AGENTS; ANTIDEPRESSIVE AGENTS; ANTIVIRAL AGENTS; BUPRENORPHINE; CARDIOVASCULAR AGENTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPNOTICS AND SEDATIVES; HYPOGLYCEMIC AGENTS; IMMUNOSUPPRESSIVE AGENTS; METHADONE; OPIATE SUBSTITUTION TREATMENT;

EID: 84880925452     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.10.027     Document Type: Review

References (29)

1. A.A. Butt Fatal lactic acidosis and pancreatitis associated with ribavirin and didanosine therapy AIDS Read 13 2003 344 348 (Pubitemid 36890378)
2. Poordad F, Lawitz E, Gordon S, Bourlière M, Vierling J, Poynard T, et al. Concomitant medication use in patients with hepatitis C genotype 1 treated with boceprevir combination therapy. In: Sixty second annual meeting of the American Association for the Study of Liver Diseases, San Francisco, California, November 4-8, 2011 [poster 937].
3. EMA. Incivo; Summary of product characteristics. 2012 [cited 2012]; Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Product-Information/human/002313/WC500115529.pdf.
4. EMA. Victrelis; Summary of product characteristics. 2012 [cited 2012]; Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Product-Information/human/002332/WC500109786.pdf.
5. A. Ghosal, Y. Yuan, W. Tong, A.D. Su, C. Gu, and S.K. Chowdhury Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor Drug Metab Dispos 39 2011 510 521
6. R.H. Ho, R.G. Tirona, B.F. Leake, H. Glaeser, W. Lee, and J. Lemke Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics Gastroenterology 130 2006 1793 1806
7. H.W. Reesink, S. Zeuzem, C.J. Weegink, N. Forestier, A. van Vliet, and J. Van de Wetering de Rooij Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study Gastroenterology 131 2006 997 1002 (Pubitemid 44498690)
8. Stone J, Wenning L, Hang Y, Su J, Gupta S, Tsai K, et al. Assessment of boceprevir pharmacokinetic/pharmacodynamic relationships for sustained viral response and occurrence of anemia from phase 3 data. In: 62nd Annual meeting of the American association for the study of liver diseases, San Francisco, California, November 4-8, 2011 [poster 1342].
9. J. Morello, S. Rodriguez-Novoa, I. Jimenez-Nacher, and V. Soriano Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C J Antimicrob Chemother 62 2008 1174 1180
10. M. Charlton Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents-a potentially lethal cocktail Hepatology 54 2011 3 5
11. V. Garg, R. van Heeswijk, J.E. Lee, K. Alves, P. Nadkarni, and X. Luo Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus Hepatology 54 2011 20 27
12. Hulskotte E, Gupta S, Xuan Y, Zutven van M, O'Mara E, Galitz L, et al. Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and the calcineurin inhibitors cyclosporine and tracolimus. In: Sixteenth annual meeting of HEP DART, Koloa, Hawaii, December 4-8, 2011 [poster 123].
13. Coilly A, Roche B, Botta-Fridlund D, Leroy V, Pageaux P, Si-Ahmed S, et al. Efficacy and safety of protease inhibitors for severe hepatitis c recurrence after liver transplantation: a first multicentric experience. In: Fortyseventh annual meeting of the European association for the study of the liver, April 18-22, 2012 [oral presentation 47].
14. Boyd S, Hadigan C, Pau A, Kovacs J, Alfaro R, Chairez C, et al. Darunavir/ritonavir does not significantly increase plasma concentrations of orally inhaled beclomethasone in healthy volunteers. In: Nineteenth conference on retroviruses and opportunistic infections (CROI), March 5-8 2012, Seattle [poster 611].
15. Garg V, Chandorkar G, Yang Y, Adda N, McNair L, Alves K, et al. The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir. In: Sixth international workshop on clinical pharmacology of hepatitis therapy, Cambridge, MA, June 22-23, 2011 [abstract PK-13].
16. Kassera C, Hughes E, Treitel M, Gupta S, O'Mara E. Clinical pharmacology of BOC: metabolism, excretion and drug-drug interactions. In: Eighteenth conference on retroviruses and opportunistic infections, Boston, Massachusetts, Ferbruary 27-March 2, 2011 [abstract 118].
17. Heeswijk van R, Vandevoorde A, Verboven P, Boogaerts G, De Paepe E, Solingen-Ristea van R, et al. The pharmacokinetic interaction between methadone and the investigational HCV protease inhibitor telaprevir. 46th Annual meeting of the European association for the study of the liver (The International Liver Congress™ 2011), Berlin, Germany, March 30-April 3, 2011 [poster 1244].
18. Hulskotte EGJ, Feng HP, Bruce RD, Webster LR, Xuan F, Lin WH, et al. Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy. In: Seventh international workshop on clinical pharmacology of hepatitis therapy, Cambridge, MS, USA, June 27-28, 2012 [abstract PK-09].
19. Luo X, Trevejo J, Heeswijk van R, Garg V. No significant effect of the HCV protease inhibitor telaprevir on pharmacokinetics and pharmacodynamics of buprenorphine in HCv-negative volunteers. In: Sixteenth annual meeting of HEP DART, Koloa, Hawaii, December 4-8, 2011 [poster 132].
20. Heeswijk van R, Boogaerts G, Paepe de E, Solingen-Ristea van R, Garg V, Beumont M. The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir. In: Fifth international workshop on clinical pharmacology of hepatitis therapy, June 23-24, 2010 [abstract 12].
21. Hulskotte E, Gupta S, Xuan Y, Zutven van M, O'Mara E, Galitz L, et al. Coadministration of the HCV protease inhibitor boceprevir has no clinically meaningful effect on the pharmacokinetics of the selective serotonin reuptake inhibitor escitalopram in healthy volunteers. In: Sixteenth annual meeting of HEP DART, Koloa, Hawaii, December 4-8, 2011 [poster 121].
22. Garg V, Chandorkar G, Smith F, Alves K, Heeswijk van R. The effect of telaprevir on the pharmacokinetics of midazolam and digoxin. In: Sixth international workshop on clinical pharmacology of hepatitis therapy, Cambridge, MA, June 22-23, 2011 [abstract PK-12].
23. Luo X, Van Heeswijk R, Alves K, Garg V. The effect of telaprevir on the pharmacokinetics of alprazolam and zolpidem in healthy volunteers. In: Sixth international workshop on clinical pharmacology of hepatitis therapy, Cambridge, MA, June 22-23, 2011 [abstract PK-11].
24. J.E. Lee, R. van Heeswijk, K. Alves, F. Smith, and V. Garg Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin Antimicrob Agents Chemother 55 2011 4569 4574
25. Hulskotte E, Gupta S, Xuan Y, Zutven van M, O'Mara E, Galitz L, et al. Pharmacokinetic evaluation of the interaction between the HCV protease inhibitor boceprevir and the HMG-CoA reductase inhibitors atorvastatin and pravastatin. In: Sixteenth annual meeting of HEP DART, Koloa, Hawaii, December 4-8, 2011 [poster 122].
26. Chu X, Cai X, Cui D, Evers R, Green M, Ghosal A, et al. In vitro assessment of drug-drug interaction potential of boceprevir as an inhibitor and inducer of drug metabolizing enzymes and transporters. In: Sixty second annual meeting of the American Association for the Study of Liver Diseases, San Francisco, California, November 4-8, 2011 [poster 378].
27. Jumes P, Feng HP, Xuan F, Youngberg S, Wagner J, Butterton J. Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and digoxin in healthy adult volunteers. In: Seventh international workshop on clinical pharmacology of hepatitis therapy, Cambridge, MS, USA, June 27-28, 2012 [abstract PK-05].
28. Garg V, Yang Y, Smith F, Adda N, Van Heeswijk R. The pharmacokinetic interaction between an oral contraceptive containing ethinyl estradiol and norethindrone and telaprevir. In: Sixth international workshop on clinical pharmacology of hepatitis therapy, Cambridge, MA, June 22-23, 2011 [abstract PK-17].
29. M. Sulkowski, T. Wright, S. Rossi, S. Arora, M. Lamb, and K. Wang Peginterferon alfa-2a does not alter the pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy Clin Pharmacol Ther 77 2005 214 224 (Pubitemid 40269136)